Loading stock data…
Fate Therapeutics, Inc. (FATE)
$2.42+0.32 (+15.24%)
Market ClosedLast close Jun 29
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fate Therapeutics, Inc. in the Healthcare sector is trading at $2.42 with a market capitalization of $259M. Wall Street consensus targets $5.41 (9 analysts), implying a +123.6% move over the next 12 months. The stock is currently 16% below its 52-week high of $2.88, remaining 74.1% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +123.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.30M↓ | $1.37M↓ | $1.74M↓ | $1.91M↑ | $1.63M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$33.00M↑ | -$34.72M | -$34.73M↑ | -$36.97M↑ | -$41.28M |
| Net Income | -$31.21M↑ | -$32.37M↓ | -$32.25M↑ | -$34.07M↑ | -$37.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$258.76M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-72.29%
Volume
Today's trading volume
5.88M
Recent News
H.C. Reiterates “Buy” Rating On Fate Therapeutics (FATE) With $7 PT
Fate Therapeutics, Inc. (NASDAQ:FATE), featuring a year-to-date gain of 102.04% and upside potential of 228.30%, secures a spot on our list of hot biotech stocks under $5 to buy. Fresh Phase 1 data presented at a major rheumatology conference gave analysts fresh reason to stay constructive on Fate Therapeutics, Inc. (NASDAQ:FATE)’s lead off-the-shelf cell therapy […]
Will Fate Therapeutics (NASDAQ:FATE) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. Indeed, Fate Therapeutics...
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of +10.87% and -25.77%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.